RATIO-SALBUTAMOL SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

SALBUTAMOL (SALBUTAMOL SULFATE)

متاح من:

TEVA CANADA LIMITED

ATC رمز:

R03AC02

INN (الاسم الدولي):

SALBUTAMOL

جرعة:

1MG

الشكل الصيدلاني:

SOLUTION

تركيب:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

طريقة التعاطي:

INHALATION

الوحدات في الحزمة:

10ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0108887007; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2018-05-18

خصائص المنتج

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate respirator solution
1 mg/mL
Bronchodilator
(beta
2
-adrenergic stimulant)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Control: 166142
DATE OF PREPARATION:
JULY 24, 2013
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
8
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................................
14
PART II: S